The Biological Treatment of Obsessive Compulsive Disorder

참고문헌 (79)

1. Goodman WK, "Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder?", J Clin Psychiatry, 51, pp.36~43 (1990)
2. Bebbington PE, "Epidemiology of obsessive-compulsive disorder", Br J Psychiatry, 35, pp.2~6 (1998)
3. Regier DA, "The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services", Arch Gen Psychiatry, 50, pp.85~94 (1993)
4. Weissman MM, "The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group", J Clin Psychiatry, 55, pp.5~10 (1994)
5. Attiullah N, "Clinical features of obsessive-compulsive disorder", Psychiatr Clin North Am, 23, pp.469~491 (2000)
6. Van Ameringen M, "The burden experienced by families of individuals with anxiety disorders. In: American Pyschiatric Association. New Research Abs- Tracts" (2005), Annual Meeting of the American Psychiatric Asso- Ciation
7. Mundo E, "Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine", Hum Psychopharmacol, 16, pp.461~468 (2001)
8. Piccinelli M, "Efficacy of drug treatment in obsessive-compulsive disorder. A metaanalytic review", Br J Psychiatry, 166, pp.424~443 (1995)
9. Greist JH, "Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis", Arch Gen Psychiatry, 52, pp.53~60 (1995)
10. Ackerman DL, "Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder", J Clin Psychopharmacol, 22, pp.309~317 (2002)
11. Mundo E, "Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder", Int Clin Psychopharmacol, 15, pp.69~76 (2000)
12. Bolton D, "Long-term course of obsessive-compulsive disorder treated in adolescence", J Am Acad Child Adolesc Psychiatry, 34, pp.1441~1450 (1995)
13. Kobak KA, "Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis", Psychopharmacology (Berl), 136, pp.205~216 (1998)
14. Canadian Psychiatric Association, "Clinical practice guidelines. Management of anxiety disorders", Can J psychiatry, 51(8), pp.9~91 (2006)
15. Zohar J, "Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators", Br J Psychiatry, 169, pp.468~474 (1996)
16. 김원, "한국형 강박장애 치료 알고리듬 2007(Ⅰ): 개발과정과 개요", 대한정신약물학회지, 18(5), pp.338~346 (2007), 대한정신약물학회
17. Bergeron R, "Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study", J Clin Psychopharmacol, 22, pp.148~154 (2002)
18. Zitterl W, "Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder", Wien Klin Wochenschr, 111, pp.439~442 (1999)
19. Denys D, "A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder", J Clin Psychopharmacol, 23, pp.568~575 (2003)
20. Hollander E, "Paroxetine OCD Study Group. Acute and long-term treatment and prevention of relapse of obsessivecompulsive disorder with paroxetine", J Clin Psychiatry, 64, pp.1113~1121 (2003)
21. Bisserbe J, "the Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder", Eur Psychiatry, 12, pp.82~93 (1997)
22. Montgomery SA, "Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder", Int Clin Psychopharmacol, 16, pp.75~86 (2001)
23. Pallanti S, "Response acceleration with mirtazapine augmentation of citalopram in obsessivecompulsive disorder patients without comorbid depression: a pilot study", J Clin Psychiatry, 65, pp.1394~1399 (2004)
24. Dougherty DD, "Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder", Int Clin Psychopharmacol, 24, pp.306~311 (2009)
25. Rabinowitz I, "High-dose escitalopram for the treatment of obsessive-compulsive disorder", Int Clin Psychopharmacol, 23, pp.49~53 (2008)
26. Galvãao-de Almeida A, "Obsessive- compulsive disorder: an open-label pilot trial of escitalopram", CNS Spectr, 12, pp.519~524 (2007)
27. Fineberg NA, "Escitalopram prevents relapse of obsessive-compulsive disorder", Eur Neuropsychopharmacol, 17, pp.430~439 (2007)
28. Ravindran LN, "Intravenous antiobsessive agents: a review", J Psychopharmacol, 24, pp.287~296 (2010)
29. Tollefson GD, "A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder", Arch Gen Psychiatry, 51, pp.559~567 (1994)
30. Tollefson GD, "Continuation treatment of OCD: double-blind and open-label experience with fluoxetine", J Clin Psychiatry, 55, pp.69~76 (1994)
31. Choi YJ, "Efficacy of treatments for patients with obsessive- compulsive disorder: a systematic review", J Am Acad Nurse Pract, 21, pp.207~213 (2009)
32. Goodman WK, "The Yale-Brown obsessive compulsive scale. II. validity", Arch Gen Psychiatry, 46, pp.1012~1016 (1989)
33. Ballenger JC, "Treatment of anxiety disorders to remission", J Clin Psychiatry, 62(12), pp.5~9 (2001)
34. Ninan PT, "High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial", J Clin Psychiatry, 67, pp.15~22 (2006)
35. Barr LC, "Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder", Am J Psychiatry, 154, pp.1293~1295 (1997)
36. Rivers-Bulkeley N, "Successful treatment of obsessive-compulsive disorder with loxapine", Am J Psychiatry, 139, pp.1345~1346 (1982)
37. McDougle CJ, "Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder", Am J Psychiatry, 147, pp.652~654 (1990)
38. McDougle CJ, "Haloperidol addition in fluvoxamine- refractory obsessive-compulsive disorder. A doubleblind, placebo-controlled study in patients with and without tics", Arch Gen Psychiatry, 51, pp.302~308 (1994)
39. McDougle CJ, "Risperidone addition in fluvoxaminerefractory obsessive-compulsive disorder: three cases", J Clin Psychiatry, 56, pp.526~528 (1995)
40. Saxena S, "Risperidone augmentation of SRI treatment for refractory obsessivecompulsive disorder", J Clin Psychiatry, 57, pp.303~306 (1996)
41. Stein DJ, "Risperidone augmentation of serotonin reuptake inhibitors in obsessivecompulsive and related disorders", J Clin Psychiatry, 58, pp.119~122 (1997)
42. Pfanner C, "Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study", Int Clin Psychopharmacol, 15, pp.297~301 (2000)
43. Matsunaga H, "A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder", J Clin Psychiatry, 70, pp.863~868 (2009)
44. Weiss EL, "Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an openlabel case series", J Clin Psychiatry, 60, pp.524~527 (1999)
45. Bogetto F, "Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial", Psychiatry Res, 96, pp.91~98 (2000)
46. Koran LM, "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder", J Clin Psychiatry, 61, pp.514~517 (2000)
47. Francobandiera G, "Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study", Can J Psychiatry, 46, pp.356~358 (2001)
48. Crocq MA, "Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment", Eur Psychiatry, 17, pp.296~297 (2002)
49. D'Amico G, "Olanzapine augmentation of paroxetine- refractory obsessive-compulsive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.619~623 (2003)
50. Bystritsky A, "Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial", J Clin Psychiatry, 65, pp.565~568 (2004)
51. Shapira NA, "A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder", Biol Psychiatry, 55, pp.553~555 (2004)
52. Marazziti D, "Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian longterm open-label study", J Psychopharmacol, 19, pp.392~394 (2005)
53. Sevincok L, "Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder", J Clin Psychopharmacol, 23, pp.448~450 (2003)
54. Denys D, "Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an openlabel study", J Clin Psychiatry, 63, pp.700~703 (2002)
55. Denys D, "A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors", J Clin Psychiatry, 65, pp.1040~1048 (2004)
56. "BMC Psychiatry", 2005, 5~
57. Fineberg NA, "Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study", Int Clin Psychopharmacol, 20, pp.223~226 (2005)
58. Denys D, "Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?", Biol Psychiatry, 61, pp.412~414 (2007)
59. Metin O, "Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial", Hum Psychopharmacol, 18, pp.463~467 (2003)
60. McDougle CJ, "Aronson SC, Anand A, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder", Am J Psychiatry, 152, pp.1812~1814 (1995)
61. Connor KM, "The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients", J Clin Psychiatry, 66, pp.49~51 (2005)
62. Savas HA, "Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study", Clin Drug Investig, 28, pp.439~442 (2008)
63. Pato MT, "A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients", Psychopharmacol Bull, 26, pp.211~214 (1990)
64. Ravizza L, "Drug treatment of obsessive-compulsive disorder (OCD): longterm trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)", Psychopharmacol Bull, 32, pp.167~173 (1996)
65. Greenberg BD, "Invasive circuitrybased neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD", Neuropsychopharmacology, 35, pp.317~336 (2010)
66. Jung HH, "Bilateral anterior cingulotomy for refractory obsessive- compulsive disorder: Long-term follow-up results", Stereotact Funct Neurosurg, 84, pp.184~189 (2006)
67. Rüuck C, "Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients", Arch Gen Psychiatry, 65, pp.914~921 (2008)
68. Bell E, "Preparing the ethical future of deep brain stimulation", Surg Neurol, 72, pp.577~586 (2009)
69. Schlapfer TE, "Deep brain stimulation for psychiatric disorders--state of the art", Adv Tech Stand Neurosurg, 34, pp.37~57 (2009)
70. Burdick A, "Deep brain stimulation for refractory obsessive-compulsive disorder", Front Biosci, 14, pp.1880~1890 (2009)
71. Read CN, "Psychiatric neurosurgery 2009: review and perspective", Semin Neurol, 29, pp.256~265 (2009)
72. Martin JL, "Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder", Cochrane Database Syst Rev (2003)
73. Ananth J, "Venlafaxine for treatment of obsessive-compulsive disorder", Am J Psychiatry, 152, pp.1832~ (1995)
74. Rauch SL, "Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases", J Clin Psychopharmacol, 16, pp.81~84 (1996)
75. Albert U, "Phenomenology of patients with early and adult onset obsessive-compulsive disorder", Epidemiol Psichiatr Soc, 11, pp.116~126 (2002)
76. Sugimoto Y, "Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice", Biol Pharm Bull, 30, pp.2399~2401 (2007)
77. Dell'osso B, "Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series", J Psychopharmacol, 22, pp.210~213 (2008)
78. Koran LM, "Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation", J Clin Psychiatry, 66, pp.515~520 (2005)
79. Vulink NC, "Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study", J Clin Psychiatry, 66, pp.228~230 (2005)

관련 논문AI추천